Vanda Pharmaceuticals Inc. (VNDA): Price and Financial Metrics

VNDA POWR Grades

• Value is the dimension where VNDA ranks best; there it ranks ahead of 99.66% of US stocks.
• VNDA's strongest trending metric is Quality; it's been moving down over the last 179 days.
• VNDA ranks lowest in Growth; there it ranks in the 18th percentile.

VNDA Stock Summary

• VNDA's current price/earnings ratio is 51.25, which is higher than 90.05% of US stocks with positive earnings.
• For VNDA, its debt to operating expenses ratio is greater than that reported by merely 9.62% of US equities we're observing.
• Equity multiplier, or assets relative to shareholders' equity, comes in at 1.19 for VANDA PHARMACEUTICALS INC; that's greater than it is for only 12.99% of US stocks.
• Stocks with similar financial metrics, market capitalization, and price volatility to VANDA PHARMACEUTICALS INC are MDRX, CMBM, NATI, RNWK, and THRM.
• VNDA's SEC filings can be seen here. And to visit VANDA PHARMACEUTICALS INC's official web site, go to www.vandapharma.com.

VNDA Valuation Summary

• In comparison to the median Healthcare stock, VNDA's EV/EBIT ratio is 300% higher, now standing at 32.
• VNDA's EV/EBIT ratio has moved up 39.9 over the prior 200 months.

Below are key valuation metrics over time for VNDA.

VNDA Growth Metrics

Its 3 year cash and equivalents growth rate is now at 94.67%.
• Its 5 year net cashflow from operations growth rate is now at 586.49%.
• The year over year cash and equivalents growth rate now stands at -7.22%.

VNDA's revenue has moved up $123,074,000 over the prior 70 months.

The table below shows VNDA's growth in key financial areas (numbers in millions of US dollars).

Date	Revenue	Operating Cash Flow	Net Income to Common Stock
2022-06-30	262.696	45.735	10.993
2022-03-31	266.205	59.067	18.072
2021-12-31	268.682	64.214	33.152
2021-09-30	268.316	56.909	34.264
2021-06-30	258.529	56.886	32.44
2021-03-31	252.837	61.875	31.501

VNDA's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.

• VNDA has a Quality Grade of B, ranking ahead of 90.12% of graded US stocks.
• VNDA's asset turnover comes in at 0.483 -- ranking 88th of 682 Pharmaceutical Products stocks.
• NEOG, CLVS, and AMRN are the stocks whose asset turnover ratios are most correlated with VNDA.

The table below shows VNDA's key quality metrics over time.